Figure 3 Proportion of patients for whom NEDA

Slides:

Advertisements

Similar presentations

Diabetic Ketoacidosis at Diagnosis Influences Complete Remission After Treatment With Hematopoietic Stem Cell Transplantation in Adolescents With Type.

Advertisements

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

STEM CELL TREATMENT IN INDIA Why to chose stem cell treatment in India?

NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: Results from the OPERA I and OPERA II, phase III studies G.

Presented By Michele Cavo at 2016 ASCO Annual Meeting

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 The US Centers for Disease Control and

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 4 Host damage from infection-related inflammatory

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Neurol. doi: /nrneurol

Current Controversies in Multiple Sclerosis Management

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Systemic immune responses to cryptococcal antigen

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Two approaches to therapeutic genome editing

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 7 The efficacy of phosphate-binder therapy

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 5 Number of AHSCT procedures for

Figure 1 Outline of the AHSCT procedure

Figure 1 The burden of chronic kidney disease (CKD)

Figure 2 Proposed model of therapeutic mechanisms of AHSCT

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Figure 2 Poststroke plasticity and recovery

Figure 2 Algorithm for immunosuppressive treatment

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Proportional motor recovery in the upper limb

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Figure 2 Phenotypes of osteoarthritis

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Pairwise correlations between selected patient-reported outcomes and performance tests in patients with MS (A) The number of pairwise correlations.

Figure 1 Timeline of pancreatic islet transplantation

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Craniospinal irradiation proton therapy for medulloblastoma

Suggested implementation approach for the prevention of oral mucositis guideline recommendations (HSCT, haematopoietic stem cell transplantation; KGF,

Figure 2 Network connections of the hypothalamus

Suggested implementation approach for the prevention of oral mucositis guideline recommendations (HSCT, haematopoietic stem cell transplantation; KGF,

Presentation transcript:

Figure 3 Proportion of patients for whom NEDA was achieved at 2 years with disease-modifying therapies and AHSCT Figure 3 | Proportion of patients for whom NEDA was achieved at 2 years with disease-modifying therapies and AHSCT. Red dots are the mean, bars represent 95% confidence intervals. The disease-modifying therapies have been approved or have been effective in phase III trials. Although studies included different patient populations, higher rates of no evidence of disease activity (NEDA) were achieved with autologous haematopoietic stem cell transplantation (AHSCT) than with any other disease-modifying therapy, including those that are considered to have high efficacy. The findings suggest that AHSCT has a more profound effect on disease activity than do current disease-modifying therapies. Muraro, P. A. et al. (2017) Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.81